Kala Pharmaceuticals, Inc. (KALA)
| Market Cap | 415.52M |
| Revenue (ttm) | 5.30M |
| Net Income (ttm) | -95.17M |
| Shares Out | 56.03M |
| EPS (ttm) | -2.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $7.46 |
| Previous Close | $7.55 |
| Change ($) | -0.09 |
| Change (%) | -1.19% |
| Day's Open | 7.52 |
| Day's Range | 7.37 - 7.54 |
| Day's Volume | 1,770,343 |
| 52-Week Range | 5.35 - 13.79 |
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies fo...
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for...
Kala Pharmaceuticals Should Have Limited Downside With Eysuvis Now Approved
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies fo...
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for...
Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q3 2020 Results - Earnings Call Transcript
Kala Pharma (KALA) delivered earnings and revenue surprises of -13.64% and 9.74%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for...
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for...
Good news from the FDA translated to bad news for Kala's share price.
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for...
Investors need to pay close attention to Kala Pharmaceuticals (KALA) stock based on the movements in the options market lately.
Kala Pharmaceuticals (KALA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc.
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc.
Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q2 2020 Results - Earnings Call Transcript
Kala Pharma (KALA) delivered earnings and revenue surprises of 0.00% and 9.89%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc.
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc.
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc.
Kala Pharma (KALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is (KALA) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for May 26th
Is (KALA) Outperforming Other Medical Stocks This Year?
Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2020 Results - Earnings Call Transcript
Kala Pharma (KALA) delivered earnings and revenue surprises of -5.88% and -57.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Kala Pharmaceuticals (NASDAQ:KALA) were flat in pre-market trading after the company reported Q1 results.
Does Kala Pharmaceuticals (KALA) have what it takes to be a top stock pick for momentum investors? Let's find out.
As of late, it has definitely been a great time to be an investor in Kala Pharmaceuticals.
Does Kala Pharmaceuticals (KALA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Coronavirus shows signs of slowdown in the United States and some other countries. While investors look for positive developments in the stock market, here are five must-buy stocks poised to g...
Picking breakout stocks is one of the most favored methods for those utilizing an active investing approach since this strategy offers the promise of superlative returns.
Kala Pharmaceuticals achieved positive results from its phase 3 STRIDE-3 study using EYSUVIS to treat patients with dry eye disease.
Is (KALA) Outperforming Other Medical Stocks This Year?
As of late, it has definitely been a great time to be an investor in Kala Pharmaceuticals, Inc. (KALA).
Top Ranked Momentum Stocks to Buy for March 10th
Investors need to pay close attention to Kala Pharmaceuticals (KALA) stock based on the movements in the options market lately.
Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q4 2019 Results - Earnings Call Transcript
Kala Pharma (KALA) delivered earnings and revenue surprises of -5.00% and -59.56%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
If STRIDE 3 trial succeeds, it would open an additional large target market in dry eye disease. An estimate of its pipeline value is provided.
Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q3 2019 Results - Earnings Call Transcript
Kala Pharma (KALA) delivered earnings and revenue surprises of -1.49% and -59.20%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Kala Pharmaceuticals had received a CRL for its corticosteroid drug known as KPI-121 0.25% for the treatment of dry eye disease.
The growing eye industry is something investors can’t ignore.
About KALA
Kala Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; ... [Read more...]
| Industry Biotechnology | IPO Date Jul 20, 2017 |
| CEO Mark Iwicki | Employees 136 |
| Stock Exchange NASDAQ | Ticker Symbol KALA |
Analyst Forecasts
According to 7 analysts, the average rating for KALA stock is "Buy." The 12-month stock price forecast is 21.50, which is an increase of 188.20% from the latest price.